Activation of p53-regulated pro-survival signals and hypoxia-independent mitochondrial targeting of TIGAR by human papillomavirus E6 oncoproteins.

[1]  M. Goodman,et al.  Prevalence of human papillomavirus genotypes in high‐grade cervical precancer and invasive cervical cancer from cancer registries before and after vaccine introduction in the United States , 2021, Cancer.

[2]  Huiqing Liu,et al.  The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR , 2021, Redox biology.

[3]  J. Reis-Filho,et al.  Genomic characterization of small cell carcinomas of the uterine cervix , 2021, Molecular oncology.

[4]  Ruohua Chen,et al.  Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma , 2020, Journal of Cancer.

[5]  Zhenhua Liu,et al.  TIGAR Promotes Tumorigenesis and Protects Tumor Cells From Oxidative and Metabolic Stresses in Gastric Cancer , 2019, Front. Oncol..

[6]  Linna Peng,et al.  Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma , 2019, bioRxiv.

[7]  Zhengwen He,et al.  TIGAR promotes growth, survival and metastasis through oxidation resistance and AKT activation in glioblastoma , 2019, Oncology letters.

[8]  J. Steinbach,et al.  Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide , 2019, International journal of molecular sciences.

[9]  J. Krijgsveld,et al.  Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling , 2019, mBio.

[10]  M. Grace,et al.  PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis , 2018, Proceedings of the National Academy of Sciences.

[11]  L. Ratner,et al.  The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30II and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma. , 2018, Virology.

[12]  J. Cardelli,et al.  Human papillomavirus type 16 E5-mediated upregulation of Met in human keratinocytes. , 2018, Virology.

[13]  Jianjun Liu,et al.  Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer , 2018, Molecular Cancer.

[14]  L. Ratner,et al.  The human T-cell leukemia virus type-1 p30II protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesis. , 2018, Virology.

[15]  B. Di Camillo,et al.  HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys , 2018, Oncogene.

[16]  F. Hoppe-Seyler,et al.  Viral E6/E7 oncogene and cellular hexokinase 2 expression in HPV-positive cancer cell lines , 2017, Oncotarget.

[17]  Renxiang Chen,et al.  Direct HPV E6/Myc interactions induce histone modifications, Pol II phosphorylation, and hTERT promoter activation , 2017, Oncotarget.

[18]  S. Graham.  The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. , 2017, Clinical science.

[19]  S. Graham.  Keratinocyte Differentiation-Dependent Human Papillomavirus Gene Regulation , 2017, Viruses.

[20]  Steven J. M. Jones,et al.  Integrated genomic and molecular characterization of cervical cancer , 2017, Nature.

[21]  Yue Xie,et al.  TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia , 2016, Journal of Hematology & Oncology.

[22]  Jian-yong Li,et al.  TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia. , 2016, Leukemia research.

[23]  K. Yan,et al.  Piwil2 is reactivated by HPV oncoproteins and initiates cell reprogramming via epigenetic regulation during cervical cancer tumorigenesis , 2016, Oncotarget.

[24]  Z. Chen,et al.  Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation. , 2016, European journal of cancer.

[25]  Dan-dan Song,et al.  TIGAR contributes to ischemic tolerance induced by cerebral preconditioning through scavenging of reactive oxygen species and inhibition of apoptosis , 2016, Scientific Reports.

[26]  M. Poljak,et al.  HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. , 2016, Journal of the National Cancer Institute.

[27]  L. Banks,et al.  E3 ligase EDD1/UBR5 is utilized by the HPV E6 oncogene to destabilize tumor suppressor TIP60 , 2016, Oncogene.

[28]  S. V. Vande Pol,et al.  The Human Papillomavirus 16 E7 Oncoprotein Attenuates AKT Signaling To Promote Internal Ribosome Entry Site-Dependent Translation and Expression of c-MYC , 2016, Journal of Virology.

[29]  O. Sansom,et al.  Opposing effects of TIGAR- and RAC1-derived ROS on Wnt-driven proliferation in the mouse intestine , 2016, Genes & development.

[30]  M. Masson,et al.  Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53 , 2015, Nature.

[31]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[32]  S. Tsao,et al.  TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells , 2014, Oncology letters.

[33]  L. Laimins,et al.  p38MAPK and MK2 Pathways Are Important for the Differentiation-Dependent Human Papillomavirus Life Cycle , 2014, Journal of Virology.

[34]  Z. Qin,et al.  A TIGAR-Regulated Metabolic Pathway Is Critical for Protection of Brain Ischemia , 2014, The Journal of Neuroscience.

[35]  L. Yin,et al.  Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. , 2014, Blood.

[36]  Yi Guo,et al.  Human Papillomavirus 16 E6 Contributes HIF-1α Induced Warburg Effect by Attenuating the VHL-HIF-1α Interaction , 2014, International journal of molecular sciences.

[37]  John M. Asara,et al.  Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors , 2013, Cell.

[38]  A. Klingelhutz,et al.  Papillomavirus E6 oncoproteins. , 2013, Virology.

[39]  Karl Munger,et al.  The papillomavirus E7 proteins. , 2013, Virology.

[40]  P. Harari,et al.  Enhanced radiation sensitivity in HPV-positive head and neck cancer. , 2013, Cancer research.

[41]  W. Gu,et al.  Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression. , 2013, Molecular cell.

[42]  Douglas Strathdee,et al.  TIGAR Is Required for Efficient Intestinal Regeneration and Tumorigenesis , 2013, Developmental cell.

[43]  K. Vousden,et al.  Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death , 2012, Proceedings of the National Academy of Sciences.

[44]  C. Meijer,et al.  PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro , 2011, Molecular Cancer.

[45]  G. Mills,et al.  Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death , 2011, Oncogene.

[46]  Anindya Dutta,et al.  Destabilization of TIP60 by human papillomavirus E6 results in attenuation of TIP60-dependent transcriptional regulation and apoptotic pathway. , 2010, Molecular cell.

[47]  Jun Qin,et al.  Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses , 2010, Nature.

[48]  K. Vousden,et al.  Modulation of intracellular ROS levels by TIGAR controls autophagy , 2009, The EMBO journal.

[49]  L. Chow,et al.  Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. , 2009, Genes & development.

[50]  Renxiang Chen,et al.  Activation and Engagement of the Htert Papillomavirus Correlates with Telomerase Cell-restricted Immortalization by Human , 2008 .

[51]  A. Teyssié,et al.  Human papillomavirus and mutated H‐ras oncogene in cervical carcinomas and pathological negative pelvic lymph nodes: A retrospective follow‐up , 2008, Journal of medical virology.

[52]  Hong Lei,et al.  Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. , 2008, Molecular cell.

[53]  John Lough,et al.  Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response , 2007, Nature.

[54]  Ronen Marmorstein,et al.  Acetylation of the p53 DNA-binding domain regulates apoptosis induction. , 2006, Molecular cell.

[55]  Yi Tang,et al.  Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. , 2006, Molecular cell.

[56]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[57]  A. Molven,et al.  Molecular analysis of the PI3K‐AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation , 2006, International journal of cancer.

[58]  M. Cole,et al.  A Human T-Cell Lymphotropic Virus Type 1 Enhancer of Myc Transforming Potential Stabilizes Myc-TIP60 Transcriptional Interactions , 2005, Molecular and Cellular Biology.

[59]  William Arbuthnot Sir Lane,et al.  The c-MYC Oncoprotein Is a Substrate of the Acetyltransferases hGCN5/PCAF and TIP60 , 2004, Molecular and Cellular Biology.

[60]  M. Grace,et al.  Mechanisms of Human Papillomavirus-Induced Oncogenesis , 2004, Journal of Virology.

[61]  Michelle S. Longworth,et al.  Pathogenesis of Human Papillomaviruses in Differentiating Epithelia , 2004, Microbiology and Molecular Biology Reviews.

[62]  D. McCance,et al.  Human Papillomavirus Type 16 E6 Activates TERT Gene Transcription through Induction of c-Myc and Release of USF-Mediated Repression , 2003, Journal of Virology.

[63]  P. Gariglio,et al.  Neocarzinostatin Induces an Effective p53-Dependent Response in Human Papillomavirus-Positive Cervical Cancer Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[64]  D. Livingston,et al.  MYC recruits the TIP60 histone acetyltransferase complex to chromatin , 2003, EMBO reports.

[65]  K. Münger,et al.  Quantitative Role of the Human Papillomavirus Type 16 E5 Gene during the Productive Stage of the Viral Life Cycle , 2003, Journal of Virology.

[66]  S. Caldeira,et al.  Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition , 2002, Oncogene.

[67]  G. Wahl,et al.  c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. , 2002, Molecular cell.

[68]  A. Harris,et al.  Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. , 2001, Cancer research.

[69]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[70]  G. Demers,et al.  Disruption of the G1/S Transition in Human Papillomavirus Type 16 E7-Expressing Human Cells Is Associated with Altered Regulation of Cyclin E , 1998, Journal of Virology.

[71]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[72]  K. Münger,et al.  Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein , 1997, Journal of virology.

[73]  D. Wazer,et al.  E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. , 1996, Cancer research.

[74]  F. Hoppe-Seyler,et al.  Functional p53 protein in human papillomavirus-positive cancer cells. , 1995, Oncogene.

[75]  D. Reisman,et al.  Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors , 1994, Molecular and cellular biology.

[76]  H. Hermeking,et al.  Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.

[77]  K.,et al.  The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. , 1994, The Journal of biological chemistry.

[78]  J. Koh,et al.  p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences , 1994, International Journal of Gynecologic Cancer.

[79]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[80]  V. Rotter,et al.  c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[81]  M. Scheffner,et al.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. , 1991, The EMBO journal.

[82]  K. Münger,et al.  Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. , 1989, The EMBO journal.

[83]  S. Påhlman,et al.  The HIF-2α-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. , 2010, Current topics in microbiology and immunology.